Bakart Co., Ltd.
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2024 (Globe Newswire) — Vaxart, Inc. (Nasdaq: VXRT) today demonstrates the potential of its norovirus oral pill vaccine candidate at IDWeek on Oct. 16 announced that they would present a study on the subject. -19, 2024 at the Los Angeles Convention Center in Los Angeles.
There are currently no approved vaccines against norovirus, so Vaxate is considered the most advanced norovirus vaccine candidate in clinical development, formulated for oral administration and designed for delivery to the gastrointestinal system. continues to work on its development. Norovirus affects approximately 21 million people in the United States each year, including 15% of children under 5 who are infected with norovirus each year. The virus has forced approximately 3 million parents to take an average of 2.2 days off from work to care for their children. Adults over 65 years of age are at increased risk for severe symptoms and clinical outcomes, including prolonged illness and death. The annual disease burden of norovirus in the United States is estimated at $10.6 billion
Presentation information:
Title: Phase 2 double-blind, placebo-controlled study shows oral tablet norovirus vaccine VXA-G1.1-NN is immunogenic, efficacious, and reduces viral shedding following norovirus infection
Speaker: Dr. Sean Tucker, Founder and Chief Scientific Officer, Vaxart
Date and time: October 17th (Thursday)
Time: 3:45pm PT
Room: 404 AB
Title: A Phase I, multicenter, non-invasive study to evaluate the safety, tolerability, and immunogenicity of an orally administered bivalent GI.1/GII.4 norovirus vaccine in healthy lactating women. Randomized, double-blind, placebo-controlled, single-dose, dose-ranging study for infants 18 years and older and breastfeeding
Speaker: Dr. Lam Nguyen, Medical Director and Head of Pharmacovigilance at Vaxart
Date and time: Saturday, October 19, 2024
Time: 2:15pm PT
Room: 403B
About Bakart
Vaxart is a clinical-stage biotechnology company developing a variety of oral recombinant vaccines based on proprietary delivery platforms. The Vaxart vaccine is designed to be administered using tablets that can be stored and transported without refrigeration and eliminate the risk of needle stick injuries. Vaxart believes that its proprietary pill vaccine delivery platform is suitable for the delivery of recombinant vaccines, and the company will develop oral versions of currently commercially available vaccines and develop recombinant vaccines for new indications. We are in a position to design. Currently, Vaxart’s development programs include tablet vaccines designed to protect against coronaviruses, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immuno-oncology indication. It is. Vaxart has extensive domestic and international patent applications covering its proprietary technology and products for oral vaccination using adenoviruses and TLR3 agonists.
story continues
contact
Vaxart Media and Investor Relations
matt steinberg
FINN Partner
IR@vaxart.com
(646) 871-8481
This press release was published by a CLEAR® certified individual.
